Neil Kumar sold $3.7M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $45.84, traded Aug 7, 2025, filed Aug 11, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.7M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-106741, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -6,784 | $45.09 | $306k | 4,751,663 | Aug 11, 2025 |
| Aug 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -13,216 | $45.64 | $603k | 4,738,447 | Aug 11, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,795 | $45.88 | $541k | 4,726,652 | Aug 11, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,205 | $46.71 | $383k | 4,718,447 | Aug 11, 2025 |
| Aug 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -6,784 | $45.09 | $306k | 948,902 | Aug 11, 2025 |
| Aug 7, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -13,216 | $45.64 | $603k | 935,686 | Aug 11, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,795 | $45.88 | $541k | 923,891 | Aug 11, 2025 |
| Aug 8, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,205 | $46.71 | $383k | 915,686 | Aug 11, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 43Moderate | BridgeBio Pharma, Inc. | Frank McCormick director | $3.9M 74,000 shares | -47% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $4.2M 80,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.3M 26,156 shares | -10% | |
| 62Notable | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $2.1M 42,237 shares | -9% | |
| 40Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $872k 17,353 shares | -4% | |
| 40Moderate | BridgeBio Pharma, Inc. | Charles J Homcy director | $14M 300,000 shares | -25% | |
| 36Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $45k 1,000 shares | -1% | |
| 28Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $841k 17,167 shares | -48% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.4M 80,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.